Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
The most recent EPS for Bioventus Inc is $0.15, beating expectations of $0.09.
How did Bioventus Inc BVS's revenue perform in the last quarter?
Bioventus Inc revenue for the last quarter is $0.15
What is the revenue estimate for Bioventus Inc?
According to 6 of Wall street analyst, the revenue estimate of Bioventus Inc range from $165.69M to $152.51M
What's the earning quality score for Bioventus Inc?
Bioventus Inc has a earning quality score of B+/56.736244. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Bioventus Inc report earnings?
Bioventus Inc next earnings report is expected in 2026-08-04
What are Bioventus Inc's expected earnings?
Bioventus Inc expected earnings is $131.14M, according to wall-street analysts.
Did Bioventus Inc beat earnings expectations?
Bioventus Inc recent earnings of $132.09M beat expectations.